Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.
Contemporary monograph on glutamate-based approaches to treat psychiatric drugs The approaches described in this text exploit both metabotropic and ionotropic glutamate receptors Focus on translational research, with many of the authors coming from industry All are acknowledged authorities in the glutamate field Includes supplementary material: sn.pub/extras
Phil Skolnick
Nervous System antidepressant effect brain brain injury depression drug drug abuse psychiatric disorder receptor research schizophrenia therapy trauma traumatic brain injury zinc
From the reviews:
“This book summarizes the translational research in the development of glutamate-based approaches to treat psychiatric disorders. Written and edited by an international group of researchers, it is an important addition to the psychiatric literature. … The intended audience includes psychiatric researchers and psychiatrists. Neuroscientists interested in the treatment of patients with psychiatric disorders also would benefit from reading this book. … The index is quite helpful. … presents a unique and novel approach that is desperately needed in the treatment of these difficult disorders.” (Michael Joel Schrift, Doody’s Review Service, February, 2011)